Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcd5)
- Development stage
- Unknown
- Lead developer
- Allergy Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Pollinex Quattro Ragweed (Ragweed MATA MPL) is an ultra-short-course allergen immunotherapy developed by Allergy Therapeutics for the treatment of seasonal allergic rhinitis and conjunctivitis caused by ragweed pollen. The vaccine consists of a ragweed pollen extract that has been chemically modified with glutaraldehyde to create an allergoid, reducing its IgE-binding capacity while maintaining its immunogenicity. This allergoid is adsorbed onto L-tyrosine, which acts as a slow-release depot, and is combined with the adjuvant monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) agonist. The combination is designed to shift the immune response from a Th2 (allergic) profile to a Th1 (protective) profile and induce T-cell tolerance. It is administered as a pre-seasonal course of four subcutaneous injections.
- Brand names
- Pollinex Quattro Ragweed
- Other names
- Ragweed MATA MPLTyrosine Adsorbed Ragweed Pollen Allergoid with MPL
02
Targets
Short ragweed pollen allergoidTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcd5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcd5).